Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC
Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo
Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC
Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety
ASCO 2026: Latest in prostate cancer
Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo
Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission
MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV